Johnson & Johnson (JNJ)
147.90
+2.16
(+1.48%)
USD |
NYSE |
Apr 19, 16:00
147.90
0.00 (0.00%)
After-Hours: 19:50
Johnson & Johnson Accounts Receivable (Quarterly): 14.87B for Dec. 31, 2023
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 14.87B |
September 30, 2023 | 14.80B |
June 30, 2023 | 16.78B |
March 31, 2023 | 16.35B |
December 31, 2022 | 14.04B |
September 30, 2022 | 15.89B |
June 30, 2022 | 16.14B |
March 31, 2022 | 15.59B |
December 31, 2021 | 15.28B |
September 30, 2021 | 14.91B |
June 30, 2021 | 14.87B |
March 31, 2021 | 14.94B |
December 31, 2020 | 13.58B |
September 30, 2020 | 14.58B |
June 30, 2020 | 14.64B |
March 31, 2020 | 14.87B |
December 31, 2019 | 14.48B |
September 30, 2019 | 14.80B |
June 30, 2019 | 14.65B |
March 31, 2019 | 14.12B |
December 31, 2018 | 14.10B |
September 30, 2018 | 14.05B |
June 30, 2018 | 14.11B |
March 31, 2018 | 14.17B |
December 31, 2017 | 13.49B |
Date | Value |
---|---|
September 30, 2017 | 13.16B |
June 30, 2017 | 13.28B |
March 31, 2017 | 12.30B |
December 31, 2016 | 11.70B |
September 30, 2016 | 11.80B |
June 30, 2016 | 12.06B |
March 31, 2016 | 11.41B |
December 31, 2015 | 10.73B |
September 30, 2015 | 11.37B |
June 30, 2015 | 11.97B |
March 31, 2015 | 11.53B |
December 31, 2014 | 10.98B |
September 30, 2014 | 11.62B |
June 30, 2014 | 12.26B |
March 31, 2014 | 12.12B |
December 31, 2013 | 11.71B |
September 30, 2013 | 12.03B |
June 30, 2013 | 11.61B |
March 31, 2013 | 11.52B |
December 31, 2012 | 11.31B |
September 30, 2012 | 11.18B |
June 30, 2012 | 10.99B |
March 31, 2012 | 10.98B |
December 31, 2011 | 10.58B |
September 30, 2011 | 10.55B |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
13.58B
Minimum
Dec 2020
16.78B
Maximum
Jun 2023
15.06B
Average
14.87B
Median
Dec 2023
Accounts Receivable (Quarterly) Benchmarks
Amgen Inc | 7.268B |
Gilead Sciences Inc | 4.66B |
Eli Lilly and Co | 9.090B |
Merck & Co Inc | 10.35B |
Shockwave Medical Inc | 114.55M |